Manuscripts
Showing 1530 manuscripts.
Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19
Citation
Xiaomei Liu, André Dallmann, Kristina Brooks, Brookie M Best, Diana F Clarke, Mark Mirochnick, John N van den Anker, Edmund V Capparelli, Jeremiah D Momper. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT: pharmacometrics & systems pharmacology. 2023. 12: 148-153. PMID: 36479969
Year
Journal
Study
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092
Citation
Maxensia Owor, Camlin Tierney, Lauren Ziemba, Renee Browning, John Moye, Bobbie Graham, Christina Reding, Diane Costello, Jennifer Norman, Lubbe Wiesner, Emma Hughes, Meghan E. Whalen, Lynette Purdue, Blandina Theophil Mmbaga, Portia Kamthunzi, Rachel Kawalazira, Kusum Nathoo, Sarah Bradford, Anne Coletti, Francesca Aweeka, Philippa Musoke. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Pediatric Infectious Disease Journal. 2021. PMID: 33464021
Year
Journal
Study
Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
Citation
Jyoti S Mathad, Rada Savic, Paula Britto, Priya Jayachandran, Lubbe Wiesner, Grace Montepiedra, Jennifer Norman, Nan Zhang, Ellen Townley, Nahida Chakhtoura, Sarah Bradford, Sandesh Patil, Stephanie Popson, Tsungai Chipato, Vanessa Rouzier, Deborah Langat, Amphan Chalermchockcharoentkit, Portia Kamthunzi, Amita Gupta, Kelly E Dooley, IMPAACT 2001 Study Team. Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clinical Infectious Diseases. 2022. PMID: 34323955
Year
Journal
Study
Prevalence of neurotoxicity symptoms among postpartum women on Isoniazid Preventive Therapy and Efavirenz-based treatment for HIV: An exploratory objective of the IMPAACT P1078 randomized trial
Citation
Patricia Mandima, Kristin Baltrusaitis, Grace Montepiedra, Lisa Aaron, Jyoti Mathad, Carolyne Onyango-Makumbi, Mandisa Nyati, James Ngocho, Gift Chareka, Ponego Ponatshego, Gaerolwe Masheto, Katie McCarthy, Patrick Jean-Philippe, Amita Gupta, Lynda Stranix-Chibanda, IMPAACT P1078 TB APPRISE study team. Prevalence of neurotoxicity symptoms among postpartum women on Isoniazid Preventive Therapy and Efavirenz-based treatment for HIV: An exploratory objective of the IMPAACT P1078 randomized trial. Journal of Acquired Immune Deficiency Syndromes. 2023. PMID: 36650479
Year
Journal
Study
Markers of intestinal immune activation and inflammation are not associated with preterm birth among women with low level HIV viremia
Citation
Anna Maya Powell, Deborah Persaud, Jean Rene Anderson, Deborah Kacanek, Yanling Huo, Kevin Psoter, Lisa R Yanek, Khalil Ghanem, Irina Burd, International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) 1025 protocol team. Markers of intestinal immune activation and inflammation are not associated with preterm birth among women with low level HIV viremia. American Journal of Reproductive Immunology. 2023. PMID: 36680487
Year
Journal
Study
Live-attenuated vaccines prevent respiratory syncytial virus (RSV)-associated illness in young children
Citation
Ruth A. Karron, Jessica E. Atwell, Elizabeth J. MacFarland, Coleen K. Cunningham, Petronella Muresan, Charlotte Perlowski, Jennifer Libous, Stephen A. Spector, Ram Yogev, Mariam Aziz, Suzanne Woods, Kimberli Wanionek, Peter L. Collins, Ursula J. Buchholz. Live-attenuated vaccines prevent respiratory syncytial virus (RSV)-associated illness in young children. American Journal of Respiratory and Critical Care Medicine. 2021. 203: 594-603. PMID: 32871092
Year
Journal
Study
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants
Citation
Elizabeth McFarland, Coleen Cunningham, Petronella Muresan, Edmund Capperelli, Charlotte Perlowski, Patricia Morgan, Betsy Smith, Rohan Hazra, Lynette Purdue, Paul Harding, Gerhard Theron, Hilda Mujuru, Allison Agwu, Murli Purswani, Mobeen Rathore, Britta Flach, Alison Taylor, Bob Lin, Adrian McDermott, John Mascola, Barney Graham, IMPAACT P1112 Team. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. Journal of Infectious Diseases. 2021. 224: 1916-1924. PMID: 34009371
Year
Journal
Study
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants
Citation
Ashenafi S. Cherkos, Sylvia M. LaCourse, Daniel A. Enquobahrie, Barbra A. Richardson, Sarah Bradford, Grace Montepiedra, Blandina T. Mmbaga, Tapiwa Mbengeranwa, Gaerolwe Masheto, Patrick Jean–Phillippe, Nahida Chakhtoura, Gerhard Theron, Adriana Weinberg, Haseena Cassim, Mpho S. Raesi, Elsie Jean, Deo Wabwire, Teacler Nematadzira, Lynda Stranix-Chibanda, Anneke C. Hesseling, Linda Aurpibul, Tapiwa Mbengeranwa, Amita Gupta, Grace John-Stewart, IMPAACT P1078 TB APPRISE Study Team. Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants. 2023. PMID: 36969345HIV-1 Remission and Possible Cure in a Woman after Haplo-Cord Blood Transplant
Citation
Jingmei Hsu, Koen Van Besien, Marshall J. Glesby, Savita Pahwa, Anne Coletti, Meredith G. Warshaw, Lawrence D Petz, Theodore B. Moore, Ya Hui Chen, Suresh Pallikkuth, Adit Dhummakupt, Ruth Cortado, Amanda Golner, Frederic Bone, Maria Baldo, Marcie Riches, John W. Mellors, Nicole H. Tobin, Renee Browning, Deborah Persaud, Yvonne Bryson, IMPAACT P1107 Team. HIV-1 Remission and Possible Cure in a Woman after Haplo-Cord Blood Transplant. Cell. 2023. 186: 1115-1126.
Year
Journal
Study
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study
Citation
Adrie Bekker, Edmund V. Capparelli, Avy Violari, Mark F. Cotton, Mae Cababasay, Jiajia Wang, Ruth Mathiba, Lubbe Wiesner, Andrew Wiznia, Pearl Samson, Renee Browning, Jack Moye, Firdose L. Nakwa, Bobbie Graham, Eric Decloedt, Helena Rabie, Mark Mirochnick, Tim R. Cressey, IMPAACT P1106 team. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV. 2022. PMID: 27936233